KRAS mutations were detected in 84.6% of PDAC cases without IPMN, 80% of PDAC cases that were concomitant with IPMN, 66.7% of PDAC cases that were derived from IPMN, and 100% of IPMN cases. The gene discussed is KRAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.